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Validation of a questionnaire 
to monitor symptoms in HIV-infected patients 
during hepatitis C treatment
Edward R. Cachay1,2* , Craig Ballard3, Bradford Colwell3, Francesca Torriani1,2, Charles Hicks1,2 
and Wm. Christopher Mathews1
Abstract 
Background: Clinicians are incorporating patient-reported outcomes in the management of HIV-infected persons 
co-infected with hepatitis C virus (HCV), but there are no validated inventories to monitor symptoms of patients dur-
ing HCV therapy.
Design: Five-year retrospective cohort analysis of persons living with HIV (PLWH) treated for HCV.
Methods: The HCV symptom-inventory (HCV-SI) was administered before, during, and after HCV treatment. Discri-
minant validity was assessed, separately, in mixed model linear regression of HCV-SI T-scores on treatment regimens 
(pegylated-interferon and ribavirin; pegylated-interferon, ribavirin, and telaprevir; and interferon-free antivirals); and 
side effect-related premature treatment discontinuation (SE-DC).
Results: From the 103 patients who completed the HCV-SI, 7% were female, 26% non-white, 32% cirrhotics and 91% 
had undetectable HIV viral loads. Most had genotype 1 (83%) and were HCV treatment-naïve (78%). We treated 19% 
of patients with pegylated-interferon and ribavirin, 22% with pegylated-interferon, ribavirin, and telaprevir and 59% 
received interferon-free antivirals. Overall, 77% achieved a sustained virologic response, and 6% discontinued HCV 
treatment due to side effects. In the treatment discrimination model, compared to the no treatment period, HCV-SI 
scores were significantly (p < 0.01) lower for interferon-free antivirals and higher for interferon-containing regimens. 
In the SE-DC model, the total HCV-SI, somatic and neuropsychiatric scores significantly predicted those patients who 
prematurely discontinued HCV treatment (P < 0.05).
Conclusions: The HCV-SI effectively differentiated among treatment regimens known to vary by side effect profiles 
and between patients with and without treatment discontinuation due to side effects. The HCV-SI may have value as 
a patient-reported outcome instrument predicting the risk of HCV treatment discontinuation.
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Background
Direct-acting antivirals (DAA) provide safe and curative 
treatment for hepatitis C virus (HCV) in patients who 
start and complete therapy successfully [1].
Clinicians treating HCV are increasingly incorporating 
patient-reported outcomes in clinical trials and routine 
care settings to better understand the interaction of 
complex patient-related factors [2]. Although clinical tri-
als have used instruments that mainly focus on disease-
specific health quality of life such as The Chronic Liver 
Disease Questionnaire-Hepatitis C Virus [3], there are 
no standard quantitative monitoring tools that can sys-
tematically track different symptom domains of patients 
while on HCV therapy. Assessing symptoms of persons 
living with HIV (PLWH) while undergoing HCV-related 
health management is important as many PLWH may 
still present with non-specific psychosomatic symptoms 
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before providers recognize potentially causative issues. 
These potential issues include relapse of substance/alco-
hol with resultant worsening depression, low perceived 
self-esteem, and/or poor adherence to HCV or antiret-
roviral medications [4]. PLWH have a high prevalence 
of medical comorbidities and ongoing barriers to care 
such as substance/alcohol use, unstable housing, and 
neuropsychiatric disease [5]. These factors can unfavora-
bly impact patient medication tolerance, perception and 
willingness to complete HCV therapy, even when treat-
ing their HCV with shorter, better-tolerated, interferon 
(IFN)-free DAA [6, 7].
We previously validated a 41-item HCV symptom 
inventory (HCV-SI) as a predictor of HCV treatment ini-
tiation using pegylated interferon and ribavirin in PLWH. 
The inventory consists of a clinically meaningful, three-
factor structure that includes neuropsychiatric, somatic, 
and sleep symptoms. The three-factor subscales demon-
strated excellent internal consistency, reliability, and pre-
dictive validity [8].
The composition of HCV treatment regimens can serve 
as a validation criterion for an HCV symptom inven-
tory, based on findings from clinical trials that symptom 
burden reflects the components of the HCV regimen. 
Therefore, we conducted the present study to compare 
the potential of a multidimensional HCV-SI score: (1) to 
discriminate between IFN-containing and IFN-free treat-
ment regimens; and (2) to identify patients with prema-
ture treatment discontinuation and/or loss to follow-up 
due to worsening symptoms or side effects.
Methods
The Owen Hepatitis Co-Infection Clinic was founded 
in April 2008 as a multidisciplinary HCV primary care-
based program at the University of California San Diego 
(UCSD) Medical Center. Since its inception, it has used 
inclusive protocols aimed at increasing HCV treatment 
uptake among PLWH, including those with ongoing 
drug use, alcohol consumption, neuropsychiatric dis-
ease, and unstable housing while fulfilling our minimum 
eligibility criteria [9]. In short, the pre-treatment assess-
ment for HCV treatment eligibility among patients with 
ongoing barriers to care required only: (1) consistent 
undetectable HIV viral load, (2) stable concurrent medi-
cal comorbidities, (3) favorable assessment by the team’s 
psychiatrist when there is a history of a psychiatric con-
dition that may interfere with treatment, (4) encouraging 
registration with a needle exchange program for those 
with ongoing injection drug use, and (5) alcohol sobri-
ety or controlled drinking for at least one month before 
HCV treatment initiation [9]. To further investigate the 
psychometric properties of the HCV-SI, we assembled a 
retrospective longitudinal cohort of adult PLWH treated 
for HCV between December 2011 and May 2016.
The HCV-SI is incorporated in the substance, alcohol 
and depression screening as part of our standard of care 
every time a patient attends the Owen HCV Hepatitis 
Co-Infection Clinic. The testing is conducted before, dur-
ing, and after HCV treatment. The first page of the evalu-
ation contains a standard validated depression inventory 
(PHQ-9/CES-D), the second page includes the NIDA-
ASSIST for illegal substance use and AUDIT-C for alco-
hol abuse assessment, and the third page contains the 
HCV-SI questions (Additional file  1: Table  S1). We use 
the online survey platform SurveyGizmo for the HCV-
SI. Regarding the HCV-SI, each symptom item includes 
a 5-category, Likert-scaled symptom severity response, 
ranging from 0 (symptom absent) to 4 (symptom very 
severe). The total HCV-SI score could range from 0 to 
164. As previously reported [4], the 41-item HCV-SI 
yielded a three-factor structure explaining 60% of the 
variance for the inventory. Factor 1 (neuropsychiatric 
symptoms) had 17 items, factor 2 (somatic symptoms) 
had eleven items, and factor 3 (sleep symptoms) had two 
items, explaining 28, 22 and 11% of the variance, respec-
tively.  Internal consistency reliability estimates of the 
three subscales were 0.93, 0.89 and 0.79 for neuropsychi-
atric, somatic and sleep symptoms, respectively. The pos-
sible ranges of observable raw scores for the HCV-SI and 
its subscales were: 0–164 (HCV-SI total), 0–44 (somatic), 
0–8 (sleep), and 0–68 (neuropsychiatric). We present raw 
sum scores, T-scores, and POMP-scores (percent of max-
imum possible) [10].
Per our HCV clinic protocol, following HCV therapy 
initiation patients are assessed monthly for the duration 
of the treatment. After treatment completion, patients 
returned after 1, 2 and 6  months during the INF-based 
era and, in the IFN-free DAA era, they returned after 
1 and 3  months for SVR ascertainment. The HCV-SI is 
self-administered by patients prior to their clinic visit, 
taking approximately 5  min to complete. The last time 
that HCV-SI was administered in any given patient was 
during the clinical visit for SVR ascertainment. Patients 
who completed the HCV-SI during at least two phases of 
HCV treatment (before, during, or after treatment) were 
included in the analysis. Demographic data, substance 
use, psychiatric history, and comorbidity data were 
obtained from medical records.
Total HCV-SI scores were examined in longitudinal 
scatter plots with linear and lowess smoothing to select 
the distribution that best fits study data. Discriminant 
validity was assessed separately for criteria treatment 
regimen composition and premature treatment dis-
continuation, in a mixed model linear regression that 
accounts for repeated measures of the HCV-SI T-scores. 
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Raw summated total HCV-SI and subscale scores were 
transformed to T-scores (with mean 50 and standard 
deviation 10) to facilitate comparison of regression model 
coefficients across models varying by SI total or subscale 
dependent variables [11]. Our analyses focused on four 
dependent variables (T-scores for the total HCV-SI and 
the somatic, sleep, and neuropsychiatric subscales) and 
two independent discrimination variables (regimen com-
position and premature treatment discontinuation). To 
examine all selected variables, we fit by maximum like-
lihood separate mixed model random intercept linear 
regressions with robust standard errors using xtmixed 
(StataCorp. 2016. Stata Statistical Software: Release 14.2. 
College Station, TX).
Examination of discriminant validity of the HCV-SI 
was conducted using mixed model regression to compare 
HCV-SI scores while patients were receiving HCV treat-
ment in the three-different groups, as follows: patients 
treated with pegylated interferon/ribavirin; those 
treated with pegylated interferon/ribavirin/telaprevir; 
and those treated with IFN-free DAA regimens. We 
estimated the treatment regimen effects using the non-
treatment periods as the comparison reference category. 
For the premature treatment discontinuation criterion, 
we dichotomized patients into two groups according to 
whether they completed (reference category) or prema-
turely discontinued treatment due to side effects or loss 
to follow-up. We reported the intraclass correlation coef-
ficient (ICC) for each model as a measure of the propor-
tion of total variance in the dependent variable accounted 
for by clustering within subjects [12].
We conducted Harrell’s c-statistics, equivalent to the 
receiver operating characteristics (ROC) area, to evalu-
ate the ability of the HCV-SI and its subscales to dis-
criminate between the levels of the two discriminating 
criteria. The Harrell’s c-statistic was estimated for binary 
specifications of the criteria while taking into account 
within-subject clustering for (1) treatment regimen 
composition (combining both interferon-containing reg-
imens in comparison with the combined no treatment 
and interferon-free DAA arms [reference category]) and 
(2) premature treatment continuation. The c-statistic 
was estimated using the Stata function somersd, which 
decomposes the ROC area into between and within 
cluster components [13]. Finally, we compared the dis-
crimination (Harrell’s c) of the total HCV Symptom 
Inventory T-score for the two discriminating outcomes 
to the comparable discrimination of PROMIS depression 
T-scores ascertained at the same clinic visits. Because 
both PHQ-9 and CES-D depression instruments were 
utilized during the study, we employed linking tables to 
transform both PHQ-9 and CES-D depression scores to 
PROMIS depression T-scores that were used in the anal-
ysis [14].
Results
During the study period, we treated 156 PLWH for HCV. 
Two patients (1.3%) were not eligible to complete the 
HCV-SI due language barriers. Of the remaining 154, 51 
were excluded [five (3.2%) declined to participate, and 
46 (29.5%) had fewer than two-time phases completed 
HCV-SI)] leaving 103 to comprise the study population. 
There were no differences in demographic characteris-
tics or prevalence of barriers to care (drug or alcohol use, 
active psychiatric disease or unstable housing), HIV risk 
factors, CD4 cell count, HIV viral suppression, HCV gen-
otype distribution, cirrhosis diagnosis, prior liver decom-
pensation or prior HCV treatment history outcomes 
between those patients included versus those excluded 
from the study (Additional file  2: Table  S2). Among the 
46 patients who completed the HCV-SI in only one-time 
phase and were excluded from the main analysis, 25 had 
documented reasons for lack of completion such as a 
new competing medical priority (12), failure to return for 
follow-up and required outreach efforts to ascertain their 
HCV treatment outcome (5), relocated soon after start-
ing HCV therapy (4), and incarceration (4). Likely patient 
fatigue was the main reason in 45.6% of patients who 
completed only one time-phase the HCV-SI (21 of 46). 
Table 1 shows the demographic, clinical, and HIV char-
acteristics of the study population which were mostly 
male (93%), white (74%), and had a history of intravenous 
drug use (IDU—70%). Most patients had HCV genotype 
1 infections and were naïve to HCV treatment. Overall, 
32% of included patients had cirrhosis. Intolerance to 
previous HCV treatment was rare (6%). At the time of 
first HCV-SI measurement, 91% of patients had a sup-
pressed HIV viral load.
By HCV treatment group, 19% (n  =  19) of study 
patients were treated with pegylated interferon/ribavi-
rin, 22% (n  =  23) with pegylated-interferon/ribavirin/
telaprevir, and 59% (n  =  61) with IFN-free DAA. The 
IFN-free DAA regimens included sofosbuvir/ledipas-
vir (n  =  39), sofosbuvir/simeprevir (n  =  11), sofosbu-
vir/ribavirin (n =  8), sofosbuvir/daclatasvir (n =  1) and 
two patients received ombitasvir/paritaprevir/ritonavir 
plus dasabuvir and ribavirin. There were no differences 
between treatment groups in gender, race/ethnicity, HIV 
risk factor, the proportion of patients with suppressed 
HIV viremia and prior HCV treatment history outcomes 
(Table 1). Overall, 77% of patients achieved an HCV sus-
tained viral response (SVR). Patients treated with IFN-
free DAA achieved the highest SVR (88%) despite the 
high proportion of patients with cirrhosis in this group. 
Patients treated with pegylated interferon/ribavirin and 
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Table 1 Demographic, HCV and HUV related characteristics of study patients
Factor Total cohort (n = 103) Peg-IFN + RBV
(n = 19)
Peg-IFN + RBV + TPV 
(n = 23)
IFN-free DAA (n = 61) P value*
Age in years, mean (SD) 49.7 (9.3) 43.6 (12.1) 45.3 (7.8) 53.2 (7.0) < 0.001
 Sex
  Female 7 (6.8%) 2 (11%) 3 (13%) 2 (3%) 0.17
  Male 96 (93.2%) 17 (89%) 20 (87%) 59 (97%)
Race
 Non-white 27 (26.2%) 5 (26%) 6 (26%) 16 (26%) 1.00
 White 76 (73.8%) 14 (74%) 17 (74%) 45 (74%)
Ethnicity
 Not hispanic 85 (82.5%) 14 (74%) 17 (74%) 54 (89%) 0.14
 Hispanic 18 (17.5%) 5 (26%) 6 (26%) 7 (11%)
HIV risk factor
 MSM 24 (23.3%) 4 (21%) 3 (13%) 17 (28%) 0.55
 Heterosexual 1 (1.0%) 0 (0%) 0 (0%) 1 (2%)
 Hemophilia 6 (5.8%) 0 (0%) 3 (13%) 3 (5%)
 MSM + IDU 45 (43.7%) 11 (58%) 11 (48%) 23 (38%)
 Heterosexual IDU 27 (26.2%) 4 (21%) 6 (26%) 17 (28%)
CD4 + in cells/mm3, median (IQR) 476.0 (341, 693) 607.0 (419, 719) 584.0 (426, 772) 417 (306, 598) 0.045
HIV viral load in copies/mL
 ≤ 50 94 (91.3%) 17 (89%) 20 (87%) 59 (97%) 1.00
 > 50 9 (8.7%) 5 (26%) 6 (26%) 16 (26%)
HCV viral load in millions IU/L, 
median (IQR)
2.0 (0.4, 5.8) 3.8 (0.3, 9.7) 3.6 (1.2, 17) 1.3 (0.4, 3.5) 0.017
HCV genotype
 1/1A/1B 86 (83.5%) 13 (68%) 23 (100%) 50 (83%) 0.014
 2 4 (3.8%) 1 (5%) 0 (0%) 3 (5%)
 3 11 (10.7%) 5 (26%) 0 (0%) 6 (10%)
 4 2 (1.9%) 0 (0%) 0 (0%) 2 (3%)
HCV treatment history
 Naïve 80 (77.7%) 19 (100%) 16 (70%) 45 (74%) 0.19
 IFN-intolerant 6 (5.8%) 0 (0%) 1 (4%) 5 (8%)
 Relapser 10 (9.7%) 0 (0%) 5 (22%) 5 (8%)
 Null responder 6 (5.8%) 0 (0%) 1 (4%) 5 (8%)
 Cure but reinfected 1 (1.0%) 0 (0%) 0 (0%) 1 (2%)
Cirrhosis status
 Non-cirrhotic 70 (68.0%) 17 (89%) 17 (74%) 36 (59%) 0.032
 Cirrhotic 33 (32.0%) 2 (11%) 6 (26%) 25 (41%)
Prior decompensation or CPS > B
 Compensated cirrhosis 20 (19.4%) 2 (11%) 4 (17%) 14 (23%) 0.13
 Prior decompensated cirrhosis 13 (12.6%) 0 (0%) 2 (9%) 11 (18%)
 Non-cirrhotic 70 (68.0%) 17 (89%) 17 (74%) 36 (59%)
SVR on treatment 1
 Yes 78 (76.5%) 12 (63%) 13 (57%) 53 (88%) 1.00
 No, null response 7 (6.9%) 2 (11%) 5 (22%) 0 (0%)
 No, relapse 4 (3.9%) 3 (16%) 0 (0%) 1 (2%)
 No, sides effects/adverse events 9 (8.8%) 2 (11%) 5 (22%) 2 (3%)
 No, died during treatment 4 (3.9%) 0 (0%) 0 (0%) 4 (7%)
Discontinuation due to severe adverse events (1st regimen)
 No 93 (91.2%) 17 (89%) 18 (78%) 58 (97%) 0.021
 Yes 9 (8.8%) 2 (11%) 5 (22%) 2 (3%)
Page 5 of 9Cachay et al. AIDS Res Ther  (2017) 14:56 
pegylated interferon/ribavirin/telaprevir achieved an 
HCV SVR in 63 and 57%, respectively.
Table  2 presents the HCV-SI total and subscale score 
distributions of 868 responses from 103 patients. The 
median number of times that the HCV-SI was completed 
by each patient while on HCV therapy was 7 (range 
4–12). Patients receiving IFN-containing regimens devel-
oped worsening neuropsychiatric and somatic symptoms 
(with stable sleep symptoms) compared to those who did 
not receive HCV treatment. In contrast, those treated 
with IFN-free DAA had significantly fewer reported 
symptoms than those who did not receive HCV treat-
ment (Table 2). The estimated coefficient beta (b) of the 
models presented in Table  3 may be interpreted using 
the following example for the total HCV-SI T-score as 
the dependent variable. For patients not on HCV ther-
apy (reference group), the average total symptom score 
was 49.42. For patients treated with IFN-free DAA, the 
average total symptom score was 47.24 (49.42–2.18), 
while the corresponding scores for patients treated with 
pegylated interferon/ribavirin/telaprevir, and pegylated 
interferon/ribavirin were 53.48 (49.42 + 4.06) and 52.31 
(49.42 +  2.89), respectively. Figure  1a, depicts the find-
ings of the treatment discrimination model, compared to 
no treatment period, where the predicted total HCV-SI 
marginal scores (fixed portion) of patients treated with 
IFN-free DAA are significantly lower than those treated 
with IFN-containing regimens (p < 0.001).
Eleven patients (11%) discontinued HCV therapy 
due to treatment-related side effects (9) or being lost to 
Table 1 continued
Factor Total cohort (n = 103) Peg-IFN + RBV
(n = 19)
Peg-IFN + RBV + TPV 
(n = 23)
IFN-free DAA (n = 61) P value*
 No. HCV-SI observations, median 
(IQR)
7.0 (4.0, 12.0) 8.0 (6.0, 15.0) 15.0 (11.0, 20.0 5.0 (4.0, 7.0) < 0.001
Barriers to care
 Ongoing drugs/alcohol use 30 (29%) 8 (42%) 7 (30%) 15 (25%) 0.34
 Active psychiatric disease 28 (27%) 8 (42%) 6 (26%) 14 (23%) 0.26
 Unstable housing 5 (5%) 1 (5%) 3 (13%) 1 (2%) 0.10
Peg-IFN Pegylated interferon, IFN Interferon, RBV Ribavirin, DAA Direct acting antiviral, MSM Men who have sex with men, IDU Intravenous drug use, HCV Hepatitis C 
virus, SVR Sustained viral response, CPS Child–Pugh score, SD Standard deviation, IQR Interquartile range, HCV-SI Hepatitis C symptom inventory
* P value for comparison of the 3 groups: Peg-IFN + RBV vs. Peg-IFN + RBV + TPV vs. IFN-Free DAA
Table 2 Distribution of  HCV-SI total and  subscale scores 
(raw, T-scores, and percent of maximum possible scores)
SD standard deviation, HCV-SI hepatitis c symptom inventory, POPM percent of 
maximum possible scores
Scale Mean (SD)
Number of patients 103
Number of responses 868
HCV-SI all symptoms [raw] 26.9 (24.0)
T-score, all symptoms 50.0 (10.0)
HCV-SI total, POMP 16.4 (14.6)
Neuropsychiatric symptoms [raw] 10.1 (9.8)
T-Score, neuropsychiatric 50.0 (10.0)
Neuropsychiatric, POMP 14.9 (14.4)
Somatic symptoms [raw] 7.2 (7.9)
T-score, somatic 50.0 (10.0)
Somatic, POMP 16.5 (18.0)
Sleep symptoms [raw] 2.3 (2.4)
T-Score, sleep 50.0 (10.0)
Sleep, POMP 29.3 (30.1)
Table 3 Mixed model regression: symptom (subscales) T-scores on treatment category
B Beta coefficient, CI Confidence intervals, Peg-IFN Pegylated interferon, RBV Ribavirin, TPV telaprevir, ICC intraclass correlation coefficient
t statistic p values: * p < 0.05; ** p < 0.01; *** p < 0.001
Treatment group
(Reference: no treatment)
T-score, all symptoms
B (95% CI)
T-score, somatic
B (95% CI)
T-score, sleep
B (95% CI)
T-score, neuropsychiatric
B (95% CI)
Peg-IFN + RBV 2.89 (1.03, 4.75)** 2.36 (0.33, 4.38)* 1.85 (−0.21, 3.91) 2.43 (0.48, 4.39)*
Peg-IFN + RBV + TPV 4.06 (2.23, 5.89)*** 4.22 (2.54, 5.89)*** 0.59 (−1.68, 2.85) 2.88 (0.94, 4.82)**
IFN-free DAA −2.18 (−3.78, − 0.58)** −1.763 (−3.22, − 0.31)* −0.99 (−2.53, − 0.55) −2.23 (−3.95, − 0.52)*
Constant 49.42 (47.69, 51.15)*** 49.29 (47.64, 50.95)*** 49.93 (48.35, 51.52)*** 49.95 (48.16, 51.75)***
No. of patients 103 103 103 103
ICC 0.62 0.63 0.60 0.59
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follow-up (2). A higher proportion of patients treated 
with IFN-containing regimens prematurely discontinued 
therapy due to side effects than those treated with IFN-
free DAA (12.8% vs. 3.1%, P = 0.02). The two patients lost 
to follow-up received IFN-DAA treatment with sofosbu-
vir/ledipasvir. Two patients discontinued their IFN-free 
DAA due to worsening insomnia, gastrointestinal side 
effects, and severe fatigue. One of the latter two patients 
had a history of decompensated cirrhosis and received 
sofosbuvir/ledipasvir. The other patient had minimal 
liver fibrosis and received ombitasvir/paritaprevir/ritona-
vir plus dasabuvir and ribavirin. The mean and standard 
deviation of the total HCV-SI T-scores of the 11 patients 
discontinuing treatment were 55.66 and 11.96, respec-
tively. In the HCV premature treatment discontinua-
tion model, the predicted total HCV-SI marginal scores 
(fixed portion) during treatment were higher (p  <  0.05) 
among those discontinuing early due to side effects than 
among those who completed treatment (Fig. 1b). Table 4 
presents the mixed model results for the regression of 
HCV-SI T-scores on premature treatment discontinu-
ation, demonstrating that the total HCV-SI significantly 
predicted those patients who prematurely discontin-
ued HCV treatment. We observed similar effects for the 
somatic and neuropsychiatric subscales but not for the 
sleep scores.
Additional file 3: Table S3 presents ROC areas adjusted 
for within-subject clustering by the source of variation 
(between- and within- subject) and by discriminating 
criteria for total HCV-SI and its subscales, as discussed 
in Methods. Discrimination was poorest for the sleep 
subscale and tended unsurprisingly to be higher for 
within-subject discrimination than between subject dis-
crimination. For the binary regimen composition cri-
terion, ROC area confidence intervals excluded the null 
value of 0.5 for the total HCV-SI and the somatic and 
neuropsychiatric subscales on both between and within-
subject estimates. For the premature treatment dis-
continuation criterion, ROC area confidence intervals 
excluded 0.5 for all within-subject estimates but only for 
Fig. 1 a Shows plots with 95% confidence interval of the average T-scores of the symptoms of each treatment group while undergoing HCV 
therapy. b Illustrates plots with 95% confidence intervals of the symptom scores when patients were dichotomized based on their hepatitis C treat-
ment premature discontinuation status due to adverse events or lost to follow-up
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the neuropsychiatric subscale for between-subject esti-
mates. Comparing the discrimination of the total HCV SI 
to that of the PROMIS depression score, the total HCV SI 
was somewhat more discriminating for both criteria, for 
both within and between subject estimates.
Discussion
This study used the HCV-SI to evaluate the evolution of 
symptoms of PLWH before, during and after HCV treat-
ment, and across three different HCV treatment eras. 
The HCV-SI discriminated among treatment regimens 
known to vary by their side effect profiles, and between 
those patients with and without premature HCV treat-
ment discontinuation due to treatment-related side 
effects or loss to follow-up. These findings suggest that 
the HCV-SI can be used to monitor PLWH symptoms 
while undergoing HCV therapy.
If treating HCV with IFN-free DAA is shorter, bet-
ter tolerated and more effective than the previous IFN-
based therapies, why are quantitative instruments to 
monitor symptoms during HCV treatment with DAA of 
value? Improved access to contemporary HCV treatment 
regimens in patients with ongoing barriers to care and 
medical comorbidities is likely [15]. Ongoing structured 
screening of patient symptoms during treatment could 
provide counseling opportunities for symptom manage-
ment and dosing recommendations (e.g. correcting the 
inappropriate use of antacids with sofosbuvir/ledipasvir) 
[16]. Use of a standardized assessment tool (such as the 
HCV-SI) facilitates a consistent approach for less expe-
rienced providers (such as nurse practitioners, physi-
cian assistants, and clinical pharmacists) to recognize 
patients at risk of treatment discontinuation [17, 18]. 
Hence, the HCV-SI allows standardization of patients’ 
self-reported safety issues. Additionally, initial licensing 
studies suggested that discontinuation of DAA treatment 
among PLWH due to side effects or lost to follow-up was 
exceedingly rare [19]. However, data from actual clinical 
care in our clinic showed that during the first 2-years of 
DAA use, 5% of PLWH discontinued HCV therapy due 
to side effects or loss to follow-up [20]. Moreover, unlike 
with IFN-based treatments, patients discontinuing IFN-
free DAA therapy are at risk of developing HCV resist-
ance and potential transmission of HCV resistance [21]. 
Finally, incorporating symptom monitoring and concur-
rent drug and alcohol screening during and after HCV 
therapy can identify behaviors that put patients at risk for 
HCV reinfection [22]. The value of quantitative invento-
ries such as the one presented here to direct appropriate 
behavior change will be valuable in this regard [23].
The HCV-SI demonstrated discriminant validity based 
on HCV treatment composition, showing that patients 
receiving DAA had significantly lower scores than those 
treated with IFN-containing regimens. Consistent with 
results from clinical trials [24], most of our patients 
treated with IFN-Free DAA tolerated their regimens well, 
despite having a high proportion of patients with cirrho-
sis and even prior liver decompensation. In fact, among 
HCV-infected PLWH, those treated with IFN-free DAA 
had lower symptom scores than did untreated patients, 
particularly notable given that 10% of the patients treated 
with IFN-free DAA also received ribavirin.
Importantly, the HCV-SI effectively predicted patients 
who prematurely discontinued HCV therapy either due 
to side effects or loss to follow-up. Patients who discon-
tinued HCV therapy due to side effects had significantly 
higher symptom scores than those who finished HCV 
therapy successfully.
This study had several limitations. First, the limited 
number of patients who prematurely discontinued IFN-
free DAA therapy limits the ability to fully explore the 
value of the instrument since changes were primarily 
reported as averages across patient groups. Secondly, 
while the mixed effect models demonstrated statistical 
significance, the ROC areas, especially for between-sub-
ject estimates, were only moderate. Third, the sample size 
is relatively small, and the results may not be generaliza-
ble to other populations with different sociodemographic 
and clinical characteristics. Finally, although we found no 
major differences between those completing HCV-SI and 
Table 4 Mixed model regression: symptom (subscales) T-scores on premature HCV treatment discontinuation due to side 
effects or loss to follow-up
B Beta coefficient, CI Confidence intervals, AE Adverse events, ICC intraclass correlation coefficient
t statistic p-values: * p < 0.05; *** p < 0.001
Factor
(Reference: all others)
T-score, all symptoms
B (95% CI)
T-score, somatic
B (95% CI)
T-score, sleep
B (95% CI)
T-score, neuropsyp.
B (95% CI)
Non-completer, AE/side effects 7.33 (1.05, 13.61)* 7.46 (0.70, 14.22)* 3.72 (−0.67, 8.10) 6.28 (1.31, 11.24)*
Constant 48.85 (47.03, 50.68)*** 48.90 (47.12, 50.68)*** 49.53 (47.85, 51.20)*** 49.06 (47.24, 
50.87)***
No. of patients 103 103 103 103
ICC 0.6 0.59 0.57 0.58
Page 8 of 9Cachay et al. AIDS Res Ther  (2017) 14:56 
those not completing it, it is possible that unmeasured 
differences existed between the included and excluded 
treated patients. Nevertheless, the results of this study 
highlight the value of incorporating quantitative tools 
such as the HCV-SI to measure and track subjective 
manifestations of PLWH to help identify those patients at 
risk of treatment discontinuation.
Conclusions
The HCV-SI showed discriminant validity across different 
HCV regimen compositions and identified patients at risk 
of HCV treatment discontinuation due to adverse events. 
Medical providers treating HCV among PLWH could 
consider the HCV-SI as a patient-reported outcome.
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